Charles Schwab Investment Management Inc. Has $148.09 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Charles Schwab Investment Management Inc. raised its stake in Insulet Co. (NASDAQ:PODD) by 43.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 636,265 shares of the medical instruments supplier’s stock after buying an additional 193,839 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Insulet were worth $148,091,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Blue Trust Inc. lifted its position in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Insulet in the 2nd quarter valued at about $32,000. Venturi Wealth Management LLC raised its stake in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares during the period. UMB Bank n.a. lifted its holdings in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares in the last quarter. Finally, CVA Family Office LLC boosted its position in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. UBS Group boosted their target price on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Barclays increased their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Citigroup lifted their price target on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Morgan Stanley increased their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, Sanford C. Bernstein began coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Stock Up 0.4 %

PODD stock opened at $262.93 on Monday. The business’s 50 day simple moving average is $241.32 and its 200 day simple moving average is $211.02. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.40. The firm has a market capitalization of $18.44 billion, a PE ratio of 45.02, a PEG ratio of 4.01 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.